These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28008605)

  • 1. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
    Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
    Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
    French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
    Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
    Hulla JE; French JE; Dunnick JK
    Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
    Pamidi A; Cardoso R; Hakem A; Matysiak-Zablocki E; Poonepalli A; Tamblyn L; Perez-Ordonez B; Hande MP; Sanchez O; Hakem R
    Cancer Res; 2007 Sep; 67(18):8527-35. PubMed ID: 17875692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.
    Shetzer Y; Kagan S; Koifman G; Sarig R; Kogan-Sakin I; Charni M; Kaufman T; Zapatka M; Molchadsky A; Rivlin N; Dinowitz N; Levin S; Landan G; Goldstein I; Goldfinger N; Pe'er D; Radlwimmer B; Lichter P; Rotter V; Aloni-Grinstein R
    Cell Death Differ; 2014 Sep; 21(9):1419-31. PubMed ID: 24832469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
    Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
    Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
    Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putative tumor-suppressor gene regions responsible for radiation lymphomagenesis in F1 mice with different p53 status.
    Hong DP; Mori N; Umesako S; Song CW; Park YG; Aizawa S; Okumoto M
    J Radiat Res; 2002 Jun; 43(2):175-85. PubMed ID: 12238332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.
    Agarwal H; Tal P; Goldfinger N; Chattopadhyay E; Malkin D; Rotter V; Attery A
    Cell Death Differ; 2024 Jul; 31(7):855-867. PubMed ID: 38745079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency.
    Leder A; McMenamin J; Zhou F; Moran JL; Beier DR; Leder P
    Oncogene; 2008 Apr; 27(17):2456-65. PubMed ID: 17952114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53+/- mice.
    Vaslet CA; Messier NJ; Kane AB
    Toxicol Sci; 2002 Aug; 68(2):331-8. PubMed ID: 12151629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
    Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
    EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
    Honma M
    Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.
    McDonnell TJ; Montes de Oca Luna R; Cho S; Amelse LL; Chavez-Reyes A; Lozano G
    J Pathol; 1999 Jul; 188(3):322-8. PubMed ID: 10419603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity.
    Woo Y; Wright SM; Maas SA; Alley TL; Caddle LB; Kamdar S; Affourtit J; Foreman O; Akeson EC; Shaffer D; Bronson RT; Morse HC; Roopenian D; Mills KD
    Oncogene; 2007 Sep; 26(41):6010-20. PubMed ID: 17384673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination.
    Boley SE; Anderson EE; French JE; Donehower LA; Walker DB; Recio L
    Cancer Res; 2000 Jun; 60(11):2831-5. PubMed ID: 10850423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome instability contributes to loss of heterozygosity in mice lacking p53.
    Shao C; Deng L; Henegariu O; Liang L; Stambrook PJ; Tischfield JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7405-10. PubMed ID: 10861008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis for loss of heterozygosity (LOH) of p53 allele in tumors derived from p53+/- and CD-1 mice following repeated subcutaneous injections of solutions containing antioxidants.
    Youssef AF; Borellini F; Jacobson-Kram D; Fort FL
    Environ Mol Mutagen; 2001; 37(1):27-30. PubMed ID: 11170239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.
    Xiong S; Pant V; Zhang Y; Aryal NK; You MJ; Kusewitt D; Lozano G
    J Pathol; 2017 Mar; 241(4):501-510. PubMed ID: 27925213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.